Browse by author
Lookup NU author(s): Emily Dookun, Dr Joao Passos, Professor Helen ArthurORCiD, Professor Gavin RichardsonORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery disease, and myocardial infarction. Furthermore, ageing is associated with a poorer prognosis to these diseases. Genetic models allowing the elimination of senescent cells revealed that an accumulation of senescence contributes to the pathophysiology of cardiovascular ageing and promotes the progression of cardiovascular disease through the expression of a proinflammatory and profibrotic senescence-associated secretory phenotype. These studies have resulted in an effort to identify pharmacological therapeutics that enable the specific elimination of senescent cells through apoptosis induction. These senescent cell apoptosis-inducing compounds are termed senolytics and their potential to ameliorate age-associated cardiovascular disease is the focus of this review.
Author(s): Dookun E, Passos JF, Arthur HM, Richardson GD
Publication type: Article
Publication status: Published
Journal: Cardiovascular Drugs and Therapy
Year: 2022
Volume: 36
Pages: 187-196
Print publication date: 01/02/2022
Online publication date: 26/09/2020
Acceptance date: 03/09/2020
Date deposited: 19/10/2020
ISSN (print): 0920-3206
ISSN (electronic): 1573-7241
Publisher: Springer Nature
URL: https://doi.org/10.1007/s10557-020-07075-w
DOI: 10.1007/s10557-020-07075-w
Altmetrics provided by Altmetric
